Skip to main content
Signal8

Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing

$MTRIPress releaseNov 9, 2026, 7:00 AM ET

Mentari Therapeutics completed its merger with InMed Pharmaceuticals and begins trading on Nasdaq today under ticker MTRI. Immediately before closing, the company raised approximately $490 million in gross private financing proceeds led by Fairmount, including conversion of $50 million of convertible notes; roughly 58.3 million shares and equivalents are outstanding post-transactions. Proceeds fund the pipeline into 2029, with initial MT-001 Phase 1 data expected mid-2027 and MT-002 on track for regulatory filing in Q1 2027 with data by year-end 2027.

Key figures

Deal Value Usd
490000000
Cash runway
into 2029
Mt002 filing
Q1 2027
Gross proceeds
490000000
Mt001 data timing
mid-2027
Mt002 data timing
year-end 2027
Convertible notes converted
50000000
Shares outstanding post transactions
58300000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.